ProCE Banner Activity

Advances in Understanding Myelodysplastic Syndromes and Individualizing Treatment

Clinical Thought

In this commentary, get my perspective on recently approved therapies for MDS, developments in the molecular underpinnings of MDS, and overcoming barriers to treatment.

Released: August 29, 2023

Share

Faculty

Michael Savona

Michael Savona, MD

Chief
Hematology, Cellular Therapy and Stem Cell Transplantation
Vanderbilt University School of Medicine
Nashville, Tennessee

Provided by

Provided by Clinical Care Options LLC, in partnership with The Myelodysplastic Syndromes Foundation, Inc.

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., Geron, and Karyopharm Therapeutics.

AbbVie Inc.

Geron

Karyopharm Therapeutics

Partners

MDS Foundation

ProCE Banner